Kylie L. Gorringe

6.5k total citations
90 papers, 3.6k citations indexed

About

Kylie L. Gorringe is a scholar working on Cancer Research, Genetics and Molecular Biology. According to data from OpenAlex, Kylie L. Gorringe has authored 90 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Cancer Research, 33 papers in Genetics and 32 papers in Molecular Biology. Recurrent topics in Kylie L. Gorringe's work include Cancer Genomics and Diagnostics (30 papers), Ovarian cancer diagnosis and treatment (27 papers) and Genomic variations and chromosomal abnormalities (19 papers). Kylie L. Gorringe is often cited by papers focused on Cancer Genomics and Diagnostics (30 papers), Ovarian cancer diagnosis and treatment (27 papers) and Genomic variations and chromosomal abnormalities (19 papers). Kylie L. Gorringe collaborates with scholars based in Australia, United Kingdom and United States. Kylie L. Gorringe's co-authors include Ian Campbell, David D.L. Bowtell, Stephen B. Fox, Ella R. Thompson, Anita Sridhar, Maria Doyle, Simone M. Rowley, Jason Li, Georgina L. Ryland and Manasa Ramakrishna and has published in prestigious journals such as Nature Communications, Nature Genetics and Bioinformatics.

In The Last Decade

Kylie L. Gorringe

87 papers receiving 3.5k citations

Peers

Countries citing papers authored by Kylie L. Gorringe

Since Specialization

Citations

This map shows the geographic impact of Kylie L. Gorringe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kylie L. Gorringe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kylie L. Gorringe more than expected).

Fields of papers citing papers by Kylie L. Gorringe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kylie L. Gorringe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kylie L. Gorringe. The network helps show where Kylie L. Gorringe may publish in the future.

Co-authorship network of co-authors of Kylie L. Gorringe

This figure shows the co-authorship network connecting the top 25 collaborators of Kylie L. Gorringe. A scholar is included among the top collaborators of Kylie L. Gorringe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kylie L. Gorringe. Kylie L. Gorringe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cellular origins of mucinous ovarian carcinoma 2025 ·The Journal of Pathology ·Nicola S. Meagher, Martin Köbel, Anthony N. Karnezis, Aline Talhouk, Michael S. Anglesio, Andrew Berchuck, Simon A. Gayther, Paul D.P. Pharoah, Penelope M. Webb, Susan J. Ramus, Kylie L. Gorringe	3
2	A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma 2024 ·NAR Genomics and Bioinformatics ·(unknown), Sam Lee, (unknown), (unknown), (unknown), Carolina Salazar, (unknown), David B. Ascher, (unknown), (unknown), (unknown), Susanne Ramm, Xiang Li, Niko Thio, Jason Li, (unknown), Kaylene J. Simpson, Kylie L. Gorringe, Jessica K. Holien	2
3	Spatial transcriptomics and the anatomical pathologist: Molecular meets morphology 2023 ·Histopathology ·Jia‐Min Pang, David J. Byrne, Alice R.T. Bergin, Franco Caramia, Sherene Loi, Kylie L. Gorringe, Stephen B. Fox	12
4	Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ 2022 ·Pathobiology ·Islam M. Miligy, Michael S. Toss, Kylie L. Gorringe, Ian O. Ellis, Andrew R. Green, Emad A. Rakha	5
5	Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours 2020 ·BMC Research Notes ·Sally M. Hunter, Genevieve Dall, Maria Doyle, Richard Lupat, Jason Li, Prue E. Allan, Simone M. Rowley, David D.L. Bowtell, (unknown), Ian Campbell, Kylie L. Gorringe	7
6	Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer 2019 ·JNCI Journal of the National Cancer Institute ·Na Li, Simone McInerny, Magnus Zethoven, Dane Cheasley, (unknown), Simone M. Rowley, Lisa Devereux, (unknown), (unknown), David J. Byrne, (unknown), Jason Li, Stephen B. Fox, Thomas John, Yoland Antill, Kylie L. Gorringe, Paul A. James, Ian Campbell	23
7	The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution 2019 ·British Journal of Cancer ·Islam M. Miligy, Michael S. Toss, Kylie L. Gorringe, Andrew H.S. Lee, Ian O. Ellis, Andrew R. Green, Emad A. Rakha	29
8	Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ 2019 ·Journal of Clinical Pathology ·Michael S. Toss, Islam M. Miligy, Kylie L. Gorringe, Karuna Mittal, Ritu Aneja, Ian O. Ellis, Andrew R. Green, Emad A. Rakha	37
9	Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS) 2018 ·British Journal of Cancer ·Michael S. Toss, Islam M. Miligy, Kylie L. Gorringe, (unknown), Hazem Khout, Ian O. Ellis, Andrew R. Green, Emad A. Rakha	39
10	When Is “Type I” Ovarian Cancer Not “Type I”? Indications of an Out-Dated Dichotomy 2018 ·Frontiers in Oncology ·Carolina Salazar, Ian Campbell, Kylie L. Gorringe	30
11	Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis 2017 ·Frontiers in Oncology ·Kylie L. Gorringe, Stephen B. Fox	75
12	Loss of heterozygosity: what is it good for? 2015 ·BMC Medical Genomics ·Georgina L. Ryland, Maria Doyle, David L. Goode, Samantha E. Boyle, David Y.H. Choong, Simone M. Rowley, Jason Li, (unknown), David D.L. Bowtell, Richard W. Tothill, Ian Campbell, Kylie L. Gorringe	67
13	Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer 2013 ·Clinical Cancer Research ·(unknown), Karen E. Sheppard, Richard B. Pearson, Ian Campbell, Kylie L. Gorringe, Kaylene J. Simpson	51
14	Pre-Invasive Ovarian Mucinous Tumors Are Characterized by CDKN2A and RAS Pathway Aberrations 2012 ·Clinical Cancer Research ·Sally M. Hunter, Kylie L. Gorringe, Michael Christie, Simone M. Rowley, David D.L. Bowtell, Ian Campbell, (unknown)	52
15	Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification? 2011 ·Clinical Cancer Research ·Sally M. Hunter, Michael S. Anglesio, Raghwa Sharma, C. Blake Gilks, Nataliya Melnyk, Yoke-Eng Chiew, Anna DeFazio, Teri A. Longacre, David G. Huntsman, Kylie L. Gorringe, Ian Campbell	17
16	Analysis of the Mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer 2011 ·BMC Cancer ·(unknown), (unknown), Manasa Ramakrishna, Georgina L. Ryland, Ian Campbell, Kylie L. Gorringe	16
17	High-Resolution Single Nucleotide Polymorphism Array Analysis of Epithelial Ovarian Cancer Reveals Numerous Microdeletions and Amplifications 2007 ·Clinical Cancer Research ·Kylie L. Gorringe, Sharoni Jacobs, Ella R. Thompson, Anita Sridhar, Wen Qiu, David Y.H. Choong, Ian Campbell	122
18	High resolution SNP array analysis of primary ovarian tumors reveals numerous microdeletions and amplifications. 2007 ·Clinical Cancer Research ·Ian Campbell, Sharoni Jacobs, Ella R. Thompson, Kylie L. Gorringe	0
19	A molecular model for sporadic human aneuploidy 2006 ·Trends in Genetics ·William Warren, Kylie L. Gorringe	22
20	Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer 2005 ·Carcinogenesis ·Kylie L. Gorringe, Suet‐Feung Chin, Paul D.P. Pharoah, (unknown), Carla Oliveíra, Paul A. Edwards, Carlos Caldas	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact